Title of article :
Safe Administration of Ipilimumab, Pembrolizumab, andNivolumab in a Patient with Metastatic Melanoma,Psoriasis, and a Previous Guillain–Barr ́e Syndrome
Author/Authors :
Cortellini, Alessio Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Parisi, Alessandro Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Fargnoli, Maria Concetta Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Cannita, Katia Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Irelli, Azzurra Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Porzio, Giampiero Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Ficorella Corrado Department of Biotechnological and Applied Clinical Sciences - University of L’Aquila - L’Aquila, Italy , Martinazzo, Claudio Department of Neurophysiopathology - St. Salvatore Hospital - L’Aquila, Italy
Abstract :
Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs),since a history of immune disorders, such as Guillain–Barr ́e syndrome (GBS) and psoriasis, is one of the major risk factors for thedevelopment of immune-related adverse events (irAEs). &is risk cannot be defined; therefore, physicians are called to managethese patients in clinical practice.Case Report. We report the case of a 62-year-old male patient affected by metastatic melanoma,with a history of GBS and psoriasis, and treated with sequential ipilimumab, pembrolizumab, and nivolumab, without significanttoxicities.Conclusion. &is case report supports that although a history of immune disorders is one of the major risk factors fordevelopment of irAEs, in some patients, it could be possible to safely administer sequential treatments with ICIs. A properdecision should be made, considering therapeutic options, disease-related risks, and those related to a recurrence of preexistingautoimmune disorders.
Keywords :
Safe Administration , Ipilimumab , Pembrolizumab , Nivolumab , Patient , Metastatic Melanoma , Psoriasis , Previous Guillain–Barr ́e Syndrome , ICIs , irAEs
Journal title :
Case Reports in Oncological Medicine
